Zions Bancorporation N.A. Has $937,000 Position in Certara, Inc. (NASDAQ:CERT)

Zions Bancorporation N.A. boosted its stake in shares of Certara, Inc. (NASDAQ:CERT) by 14.6% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 87,992 shares of the company’s stock after purchasing an additional 11,181 shares during the quarter. Zions Bancorporation N.A. owned about 0.05% of Certara worth $937,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock. Vanguard Group Inc. boosted its holdings in shares of Certara by 0.3% during the 4th quarter. Vanguard Group Inc. now owns 12,437,089 shares of the company’s stock worth $132,455,000 after buying an additional 38,068 shares during the period. Wasatch Advisors LP boosted its holdings in Certara by 22.4% during the third quarter. Wasatch Advisors LP now owns 9,015,941 shares of the company’s stock valued at $105,577,000 after acquiring an additional 1,651,076 shares during the period. Teacher Retirement System of Texas grew its position in shares of Certara by 13.9% in the fourth quarter. Teacher Retirement System of Texas now owns 4,557,951 shares of the company’s stock valued at $48,542,000 after purchasing an additional 557,348 shares during the last quarter. State Street Corp grew its position in shares of Certara by 3.4% in the third quarter. State Street Corp now owns 3,679,699 shares of the company’s stock valued at $43,089,000 after purchasing an additional 122,411 shares during the last quarter. Finally, Bank of New York Mellon Corp increased its stake in shares of Certara by 169.0% in the fourth quarter. Bank of New York Mellon Corp now owns 1,995,071 shares of the company’s stock worth $21,248,000 after purchasing an additional 1,253,385 shares during the period. Institutional investors and hedge funds own 73.96% of the company’s stock.

Certara Price Performance

Shares of Certara stock opened at $10.15 on Thursday. The firm has a market cap of $1.63 billion, a P/E ratio of -50.75, a price-to-earnings-growth ratio of 9.29 and a beta of 1.60. The firm’s 50-day simple moving average is $12.50 and its 200-day simple moving average is $11.46. Certara, Inc. has a twelve month low of $9.41 and a twelve month high of $19.18. The company has a debt-to-equity ratio of 0.28, a quick ratio of 2.86 and a current ratio of 2.86.

Analyst Ratings Changes

Several analysts recently weighed in on CERT shares. Barclays raised their target price on Certara from $12.00 to $13.00 and gave the company an “equal weight” rating in a report on Friday, February 28th. TD Cowen initiated coverage on shares of Certara in a research report on Thursday, February 27th. They set a “buy” rating and a $16.00 target price on the stock. William Blair reiterated a “market perform” rating on shares of Certara in a research note on Thursday, February 27th. Finally, Stephens restated an “overweight” rating and issued a $17.00 price target on shares of Certara in a research report on Thursday, February 27th. Four equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company. According to data from MarketBeat, Certara has a consensus rating of “Moderate Buy” and a consensus price target of $15.83.

Certara Profile

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.